Association Between Prolactin and Incidence of Cardiovascular Risk Factors in the Framingham Heart Study
BackgroundProlactin is an anterior pituitary hormone that may modulate the adverse effects of obesity. Prolactin has been associated with cardiovascular disease mortality, but less is known about whether prolactin predicts incidence of cardiovascular disease risk factors. Methods and ResultsOur samp...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-02-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.115.002640 |
| _version_ | 1818398687232000000 |
|---|---|
| author | Kate E. Therkelsen Tobin M. Abraham Alison Pedley Joseph M. Massaro Patrice Sutherland Udo Hoffmann Caroline S. Fox |
| author_facet | Kate E. Therkelsen Tobin M. Abraham Alison Pedley Joseph M. Massaro Patrice Sutherland Udo Hoffmann Caroline S. Fox |
| author_sort | Kate E. Therkelsen |
| collection | DOAJ |
| description | BackgroundProlactin is an anterior pituitary hormone that may modulate the adverse effects of obesity. Prolactin has been associated with cardiovascular disease mortality, but less is known about whether prolactin predicts incidence of cardiovascular disease risk factors. Methods and ResultsOur sample (n=3232, mean age 40.4 years, 52.1% women) was drawn from Framingham Heart Study participants who attended 2 examinations an average of 6.1 years apart. After excluding those with elevated prolactin (>30 mg/dL for women, >20 mg/dL for men), multivariable‐adjusted regressions modeled the associations between baseline prolactin and changes in cardiovascular disease risk factors. Models were adjusted for age, sex, baseline value of the risk factor, smoking status, hormone replacement therapy, and menopausal status and additionally for body mass index. Mean prolactin levels were 11.9 mg/dL (SD 5.2) in women and 8.0 mg/dL (SD 2.9) in men. No associations were observed for change in weight, body composition, total cholesterol, triglycerides, or fasting glucose. In women, for example, for each 5‐mg/dL increment in prolactin, odds of incident hypercholesterolemia were 1.06, which was not significant (95% CI 0.91–1.23, P=0.46). Some exceptions were of note. In women, for each 5‐mg/dL increment in prolactin, we observed increased odds of low high‐density lipoprotein cholesterol at follow‐up (odds ratio 1.50, 95% CI 1.18–1.91, P=0.001) that persisted after adjustment for body mass index (P=0.001). In men, a 5‐mg/dL increment in prolactin was associated with increased odds of incident hypertension (odds ratio 1.61, 95% CI 1.18–2.20 P=0.002) and incident diabetes (odds ratio 1.70, 95% CI 1.04–2.78, P=0.03). ConclusionsProlactin is not associated with a comprehensive panel of incident cardiovascular disease risk factors. Measurement of circulating prolactin levels in the community likely does not provide substantial insight into cardiometabolic risk. |
| first_indexed | 2024-12-14T07:08:44Z |
| format | Article |
| id | doaj.art-3056f22d81d9416383b412daf1a11d37 |
| institution | Directory Open Access Journal |
| issn | 2047-9980 |
| language | English |
| last_indexed | 2024-12-14T07:08:44Z |
| publishDate | 2016-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| spelling | doaj.art-3056f22d81d9416383b412daf1a11d372022-12-21T23:12:03ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802016-02-015210.1161/JAHA.115.002640Association Between Prolactin and Incidence of Cardiovascular Risk Factors in the Framingham Heart StudyKate E. Therkelsen0Tobin M. Abraham1Alison Pedley2Joseph M. Massaro3Patrice Sutherland4Udo Hoffmann5Caroline S. Fox6National Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, MADepartment of Endocrinology, Hypertension and Diabetes, Brigham and Women's Hospital and Harvard Medical School, Boston, MANational Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, MADepartment of Biostatistics, Boston University School of Public Health, Boston, MANational Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, MADepartment of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MANational Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, MABackgroundProlactin is an anterior pituitary hormone that may modulate the adverse effects of obesity. Prolactin has been associated with cardiovascular disease mortality, but less is known about whether prolactin predicts incidence of cardiovascular disease risk factors. Methods and ResultsOur sample (n=3232, mean age 40.4 years, 52.1% women) was drawn from Framingham Heart Study participants who attended 2 examinations an average of 6.1 years apart. After excluding those with elevated prolactin (>30 mg/dL for women, >20 mg/dL for men), multivariable‐adjusted regressions modeled the associations between baseline prolactin and changes in cardiovascular disease risk factors. Models were adjusted for age, sex, baseline value of the risk factor, smoking status, hormone replacement therapy, and menopausal status and additionally for body mass index. Mean prolactin levels were 11.9 mg/dL (SD 5.2) in women and 8.0 mg/dL (SD 2.9) in men. No associations were observed for change in weight, body composition, total cholesterol, triglycerides, or fasting glucose. In women, for example, for each 5‐mg/dL increment in prolactin, odds of incident hypercholesterolemia were 1.06, which was not significant (95% CI 0.91–1.23, P=0.46). Some exceptions were of note. In women, for each 5‐mg/dL increment in prolactin, we observed increased odds of low high‐density lipoprotein cholesterol at follow‐up (odds ratio 1.50, 95% CI 1.18–1.91, P=0.001) that persisted after adjustment for body mass index (P=0.001). In men, a 5‐mg/dL increment in prolactin was associated with increased odds of incident hypertension (odds ratio 1.61, 95% CI 1.18–2.20 P=0.002) and incident diabetes (odds ratio 1.70, 95% CI 1.04–2.78, P=0.03). ConclusionsProlactin is not associated with a comprehensive panel of incident cardiovascular disease risk factors. Measurement of circulating prolactin levels in the community likely does not provide substantial insight into cardiometabolic risk.https://www.ahajournals.org/doi/10.1161/JAHA.115.002640epidemiologyhormonesobesitypopulation |
| spellingShingle | Kate E. Therkelsen Tobin M. Abraham Alison Pedley Joseph M. Massaro Patrice Sutherland Udo Hoffmann Caroline S. Fox Association Between Prolactin and Incidence of Cardiovascular Risk Factors in the Framingham Heart Study Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease epidemiology hormones obesity population |
| title | Association Between Prolactin and Incidence of Cardiovascular Risk Factors in the Framingham Heart Study |
| title_full | Association Between Prolactin and Incidence of Cardiovascular Risk Factors in the Framingham Heart Study |
| title_fullStr | Association Between Prolactin and Incidence of Cardiovascular Risk Factors in the Framingham Heart Study |
| title_full_unstemmed | Association Between Prolactin and Incidence of Cardiovascular Risk Factors in the Framingham Heart Study |
| title_short | Association Between Prolactin and Incidence of Cardiovascular Risk Factors in the Framingham Heart Study |
| title_sort | association between prolactin and incidence of cardiovascular risk factors in the framingham heart study |
| topic | epidemiology hormones obesity population |
| url | https://www.ahajournals.org/doi/10.1161/JAHA.115.002640 |
| work_keys_str_mv | AT kateetherkelsen associationbetweenprolactinandincidenceofcardiovascularriskfactorsintheframinghamheartstudy AT tobinmabraham associationbetweenprolactinandincidenceofcardiovascularriskfactorsintheframinghamheartstudy AT alisonpedley associationbetweenprolactinandincidenceofcardiovascularriskfactorsintheframinghamheartstudy AT josephmmassaro associationbetweenprolactinandincidenceofcardiovascularriskfactorsintheframinghamheartstudy AT patricesutherland associationbetweenprolactinandincidenceofcardiovascularriskfactorsintheframinghamheartstudy AT udohoffmann associationbetweenprolactinandincidenceofcardiovascularriskfactorsintheframinghamheartstudy AT carolinesfox associationbetweenprolactinandincidenceofcardiovascularriskfactorsintheframinghamheartstudy |